An association of prior statin use with decreased perihematomal edema.
OBJECTIVE
To investigate the impact of statins on perihematomal edema following spontaneous supratentorial intracerebral hemorrhage (ICH).


BACKGROUND
Hematoma expansion and evolution of perihematomal edema are most commonly responsible for neurological deterioration following ICH. A possible role of statins in reducing perihematomal edema has been suggested based on studies in animal models.


METHODS
Records of consecutive ICH patients admitted to The Johns Hopkins Hospital from 1999 to 2006 were reviewed. Patients with ICH related to trauma or underlying lesions (e.g., brain tumors, aneurysms, and arterio-venous malformations) and of infratentorial location were excluded. Absolute and relative perihematomal edema were assessed on initial head CT. Using regression analysis, the impact of prior statin use on absolute and relative edema at presentation was assessed correcting for other factors possibly impacting perihematomal edema, such as age, coagulopathy, aspirin use, admission mean arterial pressure (MAP), and blood glucose.


RESULTS
A total of 125 consecutive ICH patients were studied. Patients with prior statin exposure had a mean edema volume of 13.2 +/- 9.2 cc compared to 22.3 +/- 18.3 cc in patients who were not using statins at the time of ICH. Following multiple linear regression analysis, we have identified a statistically significant association between prior statin use with reduced early absolute perihematomal edema (P = 0.035). Mean relative perihematomal edema was significantly lower in patients on statins at presentation (0.44) as opposed to 0.81 in patients with no prior statin use. This difference remained statistically significant (P = 0.021) after correcting for other variables.


CONCLUSIONS
We report the association between statin use prior to ICH and decreased absolute and relative perihematomal edema. A prospective study analyzing the role of statins in perihematomal edema reduction and the resultant effect on mortality and functional outcomes following ICH is warranted.
Naval
Neeraj S
NS
The Johns Hopkins Hospital, Baltimore, MD, USA. nnaval1@jhmi.edu
Abdelhak
Tamer A
TA
Urrunaga
Nathalie
N
Zeballos
Paloma
P
Mirski
Marek A
MA
Carhuapoma
Juan R
JR
D000368:Aged; D000369:Aged, 80 and over; D001929:Brain Edema / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000517:prevention & control; D002543:Cerebral Hemorrhage / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008875:Middle Aged; D012044:Regression Analysis; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
Stroke. 2004 Nov;35(11):2571-5
15472083
Stroke. 2004 Aug;35(8):1879-85
15178826
J Neurosurg. 1996 Jan;84(1):91-6
8613842
Stroke. 2002 Dec;33(12):2950-6
12468796
Acta Neurochir Suppl. 2006;96:81-4
16671431
Stroke. 1999 Sep;30(9):1969-73
10471452
J Neurosurg. 1997 Jul;87(1):73-8
9202268
J Neurosurg. 1993 Feb;78(2):188-91
8421201
Neurol Res. 2006 Dec;28(8):826-30
17288739
Neuropharmacology. 2006 Sep;51(4):907-13
16872642
Acta Neurochir (Wien). 1996;138(4):396-400; discussion 400-1
8738389
Ann Neurol. 2006 Jul;60(1):1-2
16802301
J Neurosurg. 2004 Jul;101(1):104-7
15255259
Stroke. 2001 Jan;32(1):162-7
11136932
J Neurosurg. 1999 Mar;90(3):491-8
10067918
J Neurosurg. 1994 Jan;80(1):51-7
8271022
Stroke. 2003 Sep;34(9):2215-20
12907821
Neurosci Res. 2007 May;58(1):12-8
17328981
J Neurosurg. 1995 Dec;83(6):1045-50
7490619
J Cereb Blood Flow Metab. 2004 Aug;24(8):926-33
15362723
Stroke. 1997 Jan;28(1):1-5
8996478
J Neurosurg. 2003 May;98(5):985-92
12744358
Circulation. 1998 Mar 31;97(12):1129-35
9537338
J Neurosurg. 1997 Feb;86(2):272-8
9010429
Acta Radiol Suppl. 1975;346:143-54
782164
Stroke. 2003 Jan;34(1):157-63
12511768
Neurology. 1994 Aug;44(8):1379-84
8058133
Neurosurgery. 2001 Apr;48(4):875-82; discussion 882-3
11322448
Stroke. 2002 Nov;33(11):2636-41
12411654
Ann Neurol. 2003 Jun;53(6):743-51
12783420
Stroke. 2001 Apr;32(4):980-6
11283400
Stroke. 2004 Nov;35(11):2587-91
15375303
Lancet. 1996 Oct 19;348(9034):1079-82
8874463
Stroke. 1996 Mar;27(3):490-7
8610319
N Engl J Med. 2001 May 10;344(19):1450-60
11346811
Neurosci Lett. 2007 Jan 16;411(3):238-42
17123715
J Neurochem. 2006 Mar;96(6):1728-39
16539688
Stroke. 2002 Nov;33(11):2631-5
12411653
Stroke. 2000 Mar;31(3):596-600
10700491
Stroke. 2000 Oct;31(10):2442-9
11022078
N Engl J Med. 2005 Feb 24;352(8):777-85
15728810
Stroke. 2004 Jul;35(7):1744-9
15166393
Stroke. 1998 Dec;29(12):2580-6
9836771
Stroke. 2000 Apr;31(4):841-7
10753985